Cargando…
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study
INTRODUCTION: CD40 ligand (CD40L) blockade has demonstrated efficacy in experimental autoimmune models. However, clinical trials of hu5c8, an anti-human CD40L IgG(1) antibody, in systemic lupus erythematosus (SLE) were halted due to an increased incidence of thrombotic events. This study evaluated C...
Autores principales: | Shock, Anthony, Burkly, Linda, Wakefield, Ian, Peters, Christopher, Garber, Ellen, Ferrant, Janine, Taylor, Frederick R., Su, Lihe, Hsu, Yen-Ming, Hutto, David, Amirkhosravi, Ali, Meyer, Todd, Francis, John, Malcolm, Sarah, Robinson, Martyn, Brown, Derek, Shaw, Stevan, Foulkes, Roland, Lawson, Alastair, Harari, Olivier, Bourne, Timothy, Maloney, Alison, Weir, Neil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558773/ https://www.ncbi.nlm.nih.gov/pubmed/26335795 http://dx.doi.org/10.1186/s13075-015-0757-4 |
Ejemplares similares
-
CD40–CD40L in Neurological Disease
por: Ots, Heather D., et al.
Publicado: (2022) -
CD40-CD40L Interaction in Immunity Against Protozoan Infections
por: Chamekh, Mustapha
Publicado: (2007) -
The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
por: Bosmans, Laura A., et al.
Publicado: (2020) -
Platelets as Key Factors in Inflammation: Focus on CD40L/CD40
por: Cognasse, Fabrice, et al.
Publicado: (2022) -
The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update
por: Senhaji, Nezha, et al.
Publicado: (2015)